AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03660644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp, Pedometer and Step Diary
Description: Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks.
Study NCT04202367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg.kg-1 bupivacaine 0.25%
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Study NCT04202367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg.kg-1 bupivacaine 0.125%
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: 60 ml IV infusion over 30 minutes
Study NCT01562041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg
Description: Ranolazine 500 mg, oral tablet, b.i.d.
Study NCT02451176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Davol Bard Soft Mesh synthetic
Description: soft mesh synthetic
Study NCT02451176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeCell Strattice Reconstructive Tissue Biologic
Description: biologic mesh
Study NCT00130325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 900mg, tablets, twice a week for 6 months
Study NCT00130325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH 900mg twice weekly for 6 months
Study NCT00130325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Isoniazid tablets 300mg
Description: Isoniazid BP 0mg twice weekly for 6 months
Study NCT04246021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Description: intravenous iron formulation
Study NCT02949362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05mg/kg
Study NCT02949362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
Study NCT01146600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin followed by placebo
Description: Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
Study NCT01146600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Clarithromycin
Description: Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
Study NCT00528619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Description: Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 20 micrograms/kg IV 2ml/minute for 30 minutes
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 40 micrograms/kg IV 2 ml/minute for 30 minutes
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 80 micrograms/kg IV 2ml/minute for 30 minutes
Study NCT03670095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactose-free memantine
Description: Lactose-free memantine tablet, 10 mg; orally as a single dose
Study NCT03670095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Lactose-containing memantine tablet, 10 mg, orally as a single dose
Study NCT00662142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
Study NCT03596762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: BAY3427080 capsules
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 160 micrograms/kg IV 2ml/minute over 30 minutes
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 320 micrograms/kg IV 2ml/minute for 30 minutes
Study NCT03596762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01378689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Storytelling online video
Description: patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
Study NCT03225326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Computer controlled 4% articaine delivery by Anaeject
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
Study NCT03225326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 4% articaine delivery by carpule syringe
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
Study NCT00564577 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CFA/I and CS17 challenge strain
Description: Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
Study NCT00540865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Description: The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
Study NCT00540865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management (CM)
Description: Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
Study NCT00540865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management (CM)
Description: Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
Study NCT03071237 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
Study NCT04148651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CO2RE® System
Description: The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
Study NCT01208103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01208103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT01208103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given CVC
Study NCT04601025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: 200 ml plain full-fat yoghurt
Study NCT04601025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea+Yoghurt
Description: 80 ml plain full-fat yoghurt + 70 gr cooked chickpea
Study NCT04601025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat+Yoghurt
Description: 80 ml plain full-fat yoghurt + 100 gr cooked oat
Study NCT03490838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 480 micrograms/kg IV 2ml/minute over 30 minutes
Study NCT00617552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 600 micrograms/kg IV 2ml/minute for 30 minutes
Study NCT02897557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulet Artificial Pancreas (AP) System
Study NCT01590108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Pyr1)apelin-13
Description: (Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
Study NCT01590108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT02733718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (near-infrared spectroscopy)
Description: mesenteric oxygenisation measurement
Study NCT03335436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
Study NCT03335436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
Study NCT02799641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: 5 mg Diazepam
Study NCT02799641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2 ml of 2% lidocaine
Study NCT02799641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill
Study NCT02799641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection
Study NCT01875029 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS + back school
Description: sham tDCS + back school
Study NCT01875029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-tDCS + back school
Description: real tDCS + back school
Study NCT04413305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screen of CRKP and infection control measure
Description: For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
Study NCT03285698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermACELL®
Description: DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
Study NCT03285698 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Integra®
Description: Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
Study NCT02089568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Amoxiclav
Description: Will receive 1.2g co-amoxiclav at induction
Study NCT02089568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo - 0.9% saline
Study NCT00526253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MyoCell
Description: Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
Study NCT00526253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MyoCell
Description: Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
Study NCT00526253 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypothermosol
Description: After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
Study NCT04081870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D power doppler US
Description: Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be supplied as a sterile liquid for IV administration.
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as a sterile liquid for IV administration.
Study NCT04310722 — intervention group
Intervention type: OTHER
Intervention: None intervention. This is an observational study.
Description: None intervention. This is an observational study.
Study NCT03245281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic Suspension (DS)
Description: Stop diuretic consumption in the 48h before the follow-up visit
Study NCT03245281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic Increase (DI)
Description: Double diuretics dosage in the 48h before the follow-up visit
Study NCT03245281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic and Medication Suspension (DMS)
Description: Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
Study NCT00869869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Study NCT00869869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Study NCT00137969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT04515290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSG-01
Description: Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
Study NCT04515290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSG-01 and Placebo
Description: One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
Study NCT04515290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
Study NCT03156972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replacment of mitral valve
Description: Mitral valve replacment by prothsis
Study NCT00668265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage is 50 - 300 mg, once daily, at bedtime.
Study NCT01464840 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: 500 mg intravenous infused over 1 hour
Study NCT02927197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
Study NCT04073992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral treatment of insomnia
Description: A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
Study NCT04260178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Education-Based Intervention Program and handbook (EBIP, hospital and home)
Description: A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
Study NCT04260178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PFT, BMI, BDI, SCMP-G
Description: pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
Study NCT04260178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFT, BMI, BDI, SCMP-G
Description: pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
Study NCT02277028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: priming and task specific training
Description: This task specific training protocol has been used in several clinical trials.
Study NCT02277028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: priming and task specific training
Description: This task specific training protocol has been used in several clinical trials.
Study NCT03191851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard device
Description: paracentesis using standard
Study NCT03191851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Device
Description: paracentesis using Melody Device
Study NCT03191851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Device with Pump
Description: paracentesis using Melody Device with Pump
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Ceftazidime
Description: Ceftazidime 1g q8/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Ceftazidime
Description: Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Meropenem
Description: Meropenem 1g q8/24, infusion over 30 minutes
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Meropenem
Description: Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Ticarcillin-clavulanate
Description: Ticarcillin/clavulanate 3.1g q6/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Ticarcillin-clavulanate
Description: Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Cefepime
Description: Cefepime 1g q8/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Cefepime
Description: Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Piperacillin tazobactam
Description: Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
Study NCT01667094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Piperacillin tazobactam
Description: Piperacillin tazobactam 4.5g q6/24
Study NCT02731079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien iDrive
Description: Surgery performed with Covidien powered stapler
Study NCT02731079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Echilon
Description: Surgery performed with Ethicon powered stapler